A method for analyzing the mechanism of ginseng improving erectile dysfunction

Abstract

The application discloses a method for analyzing the mechanism of ginseng in improving erectile dysfunction, comprising the following steps: S1, obtaining the effective components of ginseng, which include the components contained in ginseng itself and active substances generated by human metabolism; S2, obtaining the potential target points of the effective components; S3, obtaining the potential target points related to erectile dysfunction; S4, based on the above results, constructing a "effective component-target-disease" network diagram of ginseng, obtaining the common target points related to the erectile dysfunction of the effective components, and performing enrichment analysis on the key target points with a mediation centrality greater than 0.1 in the common target points; S5, performing molecular interaction ability analysis and verification on the common target points and the corresponding effective components of ginseng. The application can explore the interaction relationship between the active components of ginseng and the ED related target points from the system level, and reveal the treatment effect of ginseng on ED and the mechanism.

Description

TECHNICAL FIELD

[0001] The present application relates to the field of bioinformatics and biomedical technology, and particularly relates to a method for analyzing the mechanism of ginseng improving erectile dysfunction. BACKGROUND

[0002] Erectile dysfunction (ED) is a condition in which men are unable to achieve or maintain sufficient erection during sexual activity, affecting the quality of normal sexual life. The incidence of ED increases with age, and is associated with various chronic diseases such as cardiovascular disease, diabetes, hypertension, etc. ED not only damages the physical and mental health of men, but also affects the happiness of their partners and families. Therefore, it is an urgent need to find effective treatment methods.

[0003] Currently, the main method for treating ED is to use phosphodiesterase-5 (PDE-5) inhibitors such as sildenafil, tadalafil, etc. These drugs inhibit PDE-5 activity, increase nitric oxide (NO) signaling pathway, thereby promoting smooth muscle relaxation and blood flow increase, and improving erectile function. However, these drugs have some adverse reactions such as headache, facial flushing, indigestion, visual impairment, etc., and are ineffective or have contraindications for some ED patients, limiting the use of such drugs.

[0004] Traditional Chinese medicine, as a traditional medical system, has a long history and rich experience, and has unique insights and methods for the treatment of ED. Traditional Chinese medicine believes that the occurrence of ED is related to kidney deficiency, deficiency of qi and blood, and downward injection of damp heat, etc. Through regulating yin and yang, tonifying kidney qi, promoting blood circulation to remove blood stasis, clearing heat and dampness, etc., the purpose of restoring erectile function can be achieved. Ginseng is one of the most commonly used herbs in traditional Chinese medicine, which has the effects of tonifying vital energy, restoring pulse and preventing collapse, generating saliva and stopping thirst, calming the mind and improving intelligence, etc. It has certain improvement effect on ED patients. However, the mechanism of ginseng improving ED is not clear, and it needs to be further explored with modern scientific technology.

[0005] The present application proposes a method for analyzing the mechanism of ginseng improving erectile dysfunction based on network pharmacology and molecular docking, to reveal the interaction relationship between active ingredients of ginseng and ED related targets, and to verify the therapeutic effect of ginseng on ED. SUMMARY

[0006] To solve the problems raised in the background art, the present application provides a method for analyzing the mechanism of ginseng improving erectile dysfunction based on network pharmacology and molecular docking, which is simple to operate, comprehensive in data, and can explore the interaction relationship between active ingredients of ginseng and ED related targets from the system level, reveal the therapeutic effect of ginseng on ED and its mechanism, and provide a scientific basis for the clinical application of ginseng.

[0007] To achieve the above object, the present application provides the following technical scheme: A method for analyzing the mechanism of ginseng in improving erectile dysfunction, comprising the following steps:

[0008] S1, obtaining the efficacy components of ginseng, the efficacy components including components contained in ginseng itself and active substances produced by human metabolism;

[0009] S2, obtaining the potential target points of the efficacy components;

[0010] S3, obtaining the potential target points related to erectile dysfunction;

[0011] S4, based on the above results, constructing a "efficacy component-target-disease" network diagram of ginseng, obtaining the common target points related to erectile dysfunction of the efficacy components, and performing enrichment analysis on the key target points with a medium center degree > 0.1 in the common target points;

[0012] S5, performing molecular interaction ability analysis and verification on the common target points and corresponding ginseng efficacy components.

[0013] As a further elaboration of the technical solution:

[0014] Preferably, step S1 obtains the efficacy components by searching the traditional Chinese medicine syndrome association database SymMap, the traditional Chinese medicine system pharmacology database and analysis platform TCMSP.

[0015] Preferably, the query keyword of the traditional Chinese medicine syndrome association database SymMap is "ginseng", and the screening conditions are: 0.3 kDa≤ molecular weight≤ 1.5 kDa; the number of hydrogen bond donors is less than or equal to 5; the number of hydrogen bond acceptors is ≤ 10; the polar surface area is ≤ 140 Ų; -1≤ log partition coefficient LogP≤ 5.

[0016] Preferably, the query keyword of the traditional Chinese medicine system pharmacology database and analysis platform TCMSP is "ginseng", and the screening conditions are: oral bioavailability OB≥ 30%; drug similarity DL≥ 0.18; Caco-2 permeability≥ -0.4.

[0017] Preferably, step S2 screens the target points with an interaction probability greater than 0 with the efficacy components as the potential target points by using the SwissTargetPrediction tool.

[0018] Preferably, step S3 obtains the potential target points related to erectile dysfunction by using the OMIM and GeneCards databases.

[0019] Preferably, the enrichment analysis in step S4 includes GO function enrichment analysis and KEGG pathway enrichment analysis.

[0020] Preferably, the step S5 obtains the tertiary structure of the common target point in the step S4 through the protein structure database PDB, and verifies the molecular interaction ability of the common target point and the corresponding ginseng efficacy component by using the molecular docking tool CB-Dock.

[0021] Preferably, the receptor protein of the molecular docking is obtained according to the intermediate centrality in the step S4, and the ligand molecule is the ginseng efficacy component obtained in the step S1.

[0022] Preferably, the target point with the intermediate centrality greater than 0.1 and the probability of interaction with the ginseng efficacy component greater than 30% is screened as the receptor protein.

[0023] Compared with the prior art, the beneficial effects of the present application are:

[0024] The present application can explore the interaction relationship between the active components of ginseng and the ED-related target points from the system level, reveal the therapeutic effect of ginseng on ED and its mechanism of action, and provide a scientific basis for the clinical application of ginseng. The present application has the characteristics of simple operation, comprehensive data, etc., and can provide reference and reference for the research on the mechanism of other traditional Chinese medicines. BRIEF DESCRIPTION OF DRAWINGS

[0025] The accompanying drawings are included to provide a further understanding of the present application, and constitute a part of the specification, which together with the embodiments of the present application, serve to explain the present application, and do not constitute a limitation on the present application. In the drawings:

[0026] Figure 1 The “efficacy component-target point-disease” network diagram of ginseng and erectile dysfunction (ED);

[0027] Figure 2 The KEGG function enrichment pathway column chart of the key target points of ginseng and ED;

[0028] Figure 3 The GO function enrichment pathway network diagram of the key target points of ginseng and ED. DETAILED DESCRIPTION

[0029] The technical solutions in the embodiments of the present application will be described below in a clear and complete manner. Obviously, the described embodiments are only a part of the embodiments of the present application, not all the embodiments. Based on the embodiments in the present application, all other embodiments obtained by those skilled in the art without creative labor are within the scope of protection of the present application.

[0030] The application discloses a method for analyzing the mechanism of ginseng in improving erectile dysfunction.

[0031] The method for analyzing the mechanism of ginseng in improving erectile dysfunction comprises the following steps:

[0032] S1, obtaining the efficacy components of ginseng, wherein the efficacy components comprise components contained in ginseng itself and active substances generated by metabolism of the human body;

[0033] S2, obtaining potential action targets of the efficacy components;

[0034] S3, obtaining potential targets related to erectile dysfunction;

[0035] S4, based on the above results, constructing a "efficacy component-target-disease" network diagram of ginseng, obtaining common targets related to the efficacy components and the erectile dysfunction, and performing enrichment analysis on key targets with a mediation centrality greater than 0.1 in the common targets;

[0036] S5, performing molecular interaction ability analysis and verification on the common targets and corresponding efficacy components of ginseng.

[0037] Further, step S1 obtains the efficacy components by searching a traditional Chinese medicine syndrome association database SymMap, a traditional Chinese medicine systematic pharmacology database and an analysis platform TCMSP.

[0038] Further, the key word of the traditional Chinese medicine syndrome association database SymMap is "ginseng", and the screening condition is: 0.3 kDa≤ molecular weight≤ 1.5 kDa; the number of hydrogen bond donors is less than or equal to 5; the number of hydrogen bond acceptors is less than or equal to 10; the polar surface area is less than or equal to 140 Ų; -1≤ logarithmic partition coefficient LogP≤ 5.

[0039] Further, the key word of the traditional Chinese medicine systematic pharmacology database and the analysis platform TCMSP is "ginseng", and the screening condition is: oral bioavailability OB≥ 30%; drug similarity DL≥ 0.18; Caco-2 permeability≥ -0.4.

[0040] Further, step S2 screens, by using a SwissTargetPrediction tool, targets with a probability of interaction with the efficacy components greater than 0 as the potential action targets.

[0041] Further, the step S3 obtains potential targets related to erectile dysfunction through OMIM and GeneCards databases. OMIM is the abbreviation of "Online Mendelian Inheritance in Man", an online database of human Mendelian traits and disorders, which is compiled and maintained by the Johns Hopkins University School of Medicine. Genecards is a comprehensive database of searchable genes, which can obtain information of almost all known human genes. Genecards automatically integrates resources from about 150 databases centered on genes, including genomics, transcriptomics, proteomics, genetics, clinical and functional information, etc.

[0042] Further, the enrichment analysis in step S4 includes GO function enrichment analysis and KEGG pathway enrichment analysis. GO function enrichment analysis is a bioinformatics analysis method for studying gene or protein sets, which compares the input gene or protein set with the functional annotation in the known Gene Ontology (GO) annotation database to determine which functions are enriched in the input set. GO function annotation is a standardized method for classifying and annotating the functions of genes or proteins, which divides functions into three levels: molecular function, cellular component, and biological process. GO function enrichment analysis can help researchers understand the functional characteristics and biological significance of the input gene or protein set. Through GO function enrichment analysis, significant enrichment of functions in the input set can be identified, and the biological processes, cellular components and molecular functions that the gene or protein set can participate in can be inferred. This is of great significance for studying the functions and interactions of genes or proteins in specific biological processes, and can provide clues for further experimental design and interpretation. KEGG function enrichment analysis is a bioinformatics analysis method for determining the biological functions and metabolic pathways enriched in a gene set. This analysis method is based on the KEGG database, which compares the significant differences between the input gene set and the gene set in the KEGG database to identify biological functions and metabolic pathways related to the input gene set. KEGG function enrichment analysis can help researchers understand the functional characteristics of the gene set, reveal the role of the gene set in biological processes, and provide important references for further experimental design and data interpretation.

[0043] Further, the step S5 obtains the tertiary structure of the common target points in step S4 through the protein structure database PDB, and uses the molecular docking tool CB-Dock to analyze and verify the molecular interaction ability of the common target points and the corresponding ginseng efficacy components.

[0044] Further, the receptor proteins of molecular docking are obtained according to the intermediate centrality in step S4, and the ligand molecules are the ginseng efficacy components obtained in step S1.

[0045] Further, the target points with the intermediate centrality >0.1 and the probability of interaction with the ginseng efficacy components >30% are screened as the receptor proteins. Embodiment

[0046] 1. The ginseng efficacy components are obtained by searching the SymMap and TCMSP databases.

[0047] The keyword for searching the SymMap database is “ginseng”, and the screening conditions are: a) the molecular weight is between 0.3 and 1.5 kDa; b) the number of hydrogen bond donors is less than or equal to 5; c) the number of hydrogen bond acceptors is less than or equal to 10; d) the polar surface area is less than or equal to 140 Ų; and e) the logarithmic partition coefficient (LogP) is between -1 and 5. After screening, a total of 12 ginseng efficacy components are obtained from the SymMap database, which are Protopine (Pubchem CID: 4970), Quercetin (MOL000098), Stepholidine (MOL000627), morin (MOL000737), bicuculline (MOL000791), Lignan (MOL002695), Celabenzine (MOL005314), Gomisin B (MOL005357), suchilactone (MOL005384), papaverine (MOL006980), yohimbine (MOL008488), and Alisol C monoacetate (MOL010803).

[0048] The TCMSP database query keyword is "Panax ginseng", and the screening conditions are: a) oral bioavailability (OB) > 30%; b) drug similarity (DL) > 0.18; c) Caco-2 permeability > -0.4. A total of 20 ingredients were screened, namely beta-sitosterol (MOL000358), kaempferol (MOL000422), stigmasterol (MOL000449), fumarine (MOL000787), diop (MOL002879), inermin (MOL003648), chrysanthemaxanthin (MOL004492), aposiopolamine (MOL005308), celabenzine (MOL005314), deoxyharringtonine (MOL005317), dianthramine (MOL005318), arachidonate (MOL005320), frutinone A (MOL005321), ginsenoside-Rh4_qt (MOL005348), girinimbin (MOL005356), gomisin B (MOL005357), panaxadiol (MOL005376), suchilactone (MOL005384), alexandrin_qt (MOL005399), and ginsenoside Rg5_qt (MOL005401). Therefore, a total of 32 functional components of Panax ginseng were obtained.

[0049] 2. Obtain the potential action targets of each functional component by the SwissTargetPrediction tool.

[0050] The screening condition for potential targets is that the probability of interaction is greater than 0. After screening, a total of 730 potential action targets of each functional component were obtained, of which Quercetin, kaempferol and papaverine had the most reliable targets (interaction probability of 100%) with 68, 17 and 7, respectively.

[0051] 3. Obtain potential targets related to erectile dysfunction through OMIM and GeneCards disease databases.

[0052] The query keyword is "erectile dysfunction". After the query, there are 1950 potential target points related to ED, among which 1794 are obtained from the GeneCards database, 191 are obtained from OMIM, and 35 are repeated. The most important ones are nitric oxide synthase 3 (NOS3), phosphodiesterase-5 (PDE5A), androgen receptor (AR), vascular endothelial growth factor (VEGF), angiotensin II type 1 receptor (AGTR1), nerve growth factor (NGF), neuronal nitric oxide synthase (NOS1), angiotensin-converting enzyme (ACE), endothelin-1 receptor (EDNRA), endothelin-2 receptor (EDNRB), angiotensin II type 2 receptor (AGTR2), vascular endothelial growth factor receptor 2 (KDR), vascular endothelial growth factor receptor 3 (FLT4), cholesterol side chain cleavage enzyme (CYP11A1), cholesterol side chain cleavage enzyme family member 17 (CYP17A1), cholesterol side chain cleavage enzyme family member 19 (CYP19A1), cholesterol side chain cleavage enzyme family member 21 (CYP21A2), cholesterol side chain cleavage enzyme family member 27 (CYP27A1), sex hormone binding globulin (SHBG), 5α-reductase 2 (SRD5A2), estrogen receptor alpha (ESR1), estrogen receptor beta (ESR2), prostaglandin E receptor 3 (PTGER3), prostaglandin E receptor 4 (PTGER4), and prostaglandin D synthase (PTGDS).

[0053] 4. The "efficacy component-target-disease" network diagram of ginseng was constructed by igraph and ggraph software, and the key target points in the network were subjected to GO function enrichment analysis and KEGG function enrichment analysis to reveal how the active components of ginseng exert their pharmacological effects through multi-target and multi-pathway combined regulation and improve erectile dysfunction.

[0054] As Figure 1As shown in the network diagram, the effective components of ginseng are represented by red nodes, the targets of the effective components of ginseng are represented by black nodes other than the potential targets of ED, the ED-related targets other than the targets of the effective components of ginseng are represented by blue nodes, and the common targets of the effective components of ginseng and ED are represented by orange nodes. According to the network diagram, there are 292 common targets of the effective components of ginseng and ED-related targets, of which 49 are key targets (intermediate centrality greater than 0.1), namely androgen receptor (AR), estrogen receptor alpha (ESR1), estrogen receptor beta (ESR2), serotonin transporter (SLC6A4), acetylcholinesterase (BCHE), cholinergic receptor M2 (CHRM2), hydroxyketone reductase 1 (HSD11B1), adenosine A1 receptor (ADORA1), glycogen synthase kinase-3 beta (GSK3B), cyclin-dependent kinase 2 (CDK2), epidermal growth factor receptor (EGFR), insulin-like growth factor 1 receptor (IGF1R), coagulation factor II (F2), fusion tumor-related protein 1 (PIM1), vascular endothelial cell growth factor receptor (KDR), cyclin-dependent kinase 1 (CDK1), tyrosine kinase receptor (MET), beta amyloid precursor protein (APP), polymerase-1 (PARP1), telomerase reverse transcriptase (TERT), dopamine transporter (SLC6A3), adrenergic alpha 1D receptor (ADRA1D), checkpoint kinase 1 (CHEK1), mitogen-activated protein kinase 8 (MAPK8), Janus kinase 1 (JAK1), Janus kinase 2 (JAK2), Leucine-rich repeat kinase 2 (LRRK2), phosphatidylinositol 3-kinase alpha (PIK3CA), mammalian target of rapamycin (MTOR), phosphatidylinositol 3-kinase gamma (PIK3CG), protein kinase DNA-dependent catalytic subunit (PRKDC), 5-hydroxytryptamine receptor 2C (HTR2C), mitogen-activated protein kinase 14 (MAPK14), phosphodiesterase 10A (PDE10A), phosphodiesterase 4B (PDE4B), epidermal growth factor receptor 2 (ERBB2), phosphodiesterase 5A (PDE5A), 5-hydroxytryptamine receptor 2A (HTR2A), neurotrophin receptor 1 (NTRK1), phosphodiesterase 2A (PDE2A), phosphodiesterase 4D (PDE4D), renin (REN), cannabinoid receptor 1 (CNR1), cell division cycle protein 25A (CDC25A), cell division cycle protein 25B (CDC25B), mitogen-activated protein kinase 10 (MAPK10), adenosine A3 receptor (ADORA3), transforming growth factor beta receptor 1 (TGFBR1), and endothelial selectin (SELE).

[0055] The above target points have multiple interactions with ginseng efficacy components, indicating that ginseng can regulate the occurrence and development of ED through multiple pathways.

[0056] To further explore the function and pathway of the key target points, GO function enrichment analysis and KEGG function enrichment analysis were performed, and the results are shown in Figure 2 and Figure 3 .

[0057] The function enrichment analysis results show that the ED-related target points regulated by ginseng efficacy components are mainly involved in protein serine / threonine kinase activity, protein serine kinase activity, transmembrane receptor protein kinase activity, protein tyrosine kinase activity, 3', 5'-cyclic nucleotide phosphodiesterase activity, and PI3K-Akt pathway regulation. The above functions and pathways are closely related to the pathogenesis of ED, indicating that ginseng may improve the symptoms of ED by affecting such functions and pathways.

[0058] 5. Verified by molecular docking.

[0059] The tertiary structure of the common target points of ginseng and ED in the interaction network was obtained from the PDB database, and the molecular interaction ability of the target points and their corresponding ginseng active ingredients was analyzed using the CB-Dock molecular docking tool to verify the regulation mechanism of ginseng on ED. The receptor proteins in this process were obtained according to the intermediate centrality, with a screening condition of intermediate centrality greater than 0.1. At the same time, ginseng efficacy components with significant interaction with the screened receptor proteins were selected as ligand molecules based on the standard of interaction probability greater than 30% to perform molecular docking verification.

[0060] The results of molecular docking are shown in the following table (Table 1):

[0061] Table 1 Molecular docking results of ginseng efficacy components and ED-related key target points

[0062] Target protein (PDB ID) Ligand molecule (TCMSP ID) Score AR (1T7R) MOL005399 -7.9 ESR2 (1L2J) MOL000098 -8.5 ESR2 (1L2J) MOL000422 -8.7 ESR2 (1L2J) MOL000449 -6.9 ESR2 (1L2J) MOL005399 -5.8 ESR2 (1L2J) MOL000737 -8.7 PDE5A (5JO3) MOL006980 -8.3 PDE2A (1YKD) MOL006980 -7.7 PDE10A (4MVH) MOL006980 -8.0 EGFR (4I23) MOL000098 -8.8 EGFR (4I23) MOL000422 -8.4 IGF1R (7XLC) MOL000098 -8.4 IGF1R (7XLC) MOL000422 -8.3 KDR (1WQ9) MOL000098 -7.1 KDR (1WQ9) MOL000422 -7.1 MET (6GCU) MOL000098 -7.6 MET (6GCU) MOL000422 -7.5 GSK3B (4J1R) MOL000098 -7.5 GSK3B (4J1R) MOL000422 -7.6 CDK2 (1JSV) MOL000098 -8.1 CDK2 (1JSV) MOL000422 -8.0 PIM1 (7SXO) MOL000098 -8.2 PIM1 (7SXO) MOL000422 -8.3 CDK1 (4YC6) MOL000098 -8.1 CDK1 (4YC6) MOL000422 -8.2 PIK3CG (7MEZ) MOL000098 -8.3

[0063] The molecular docking results show that the functional components of ginseng, i.e. papaverine (MOL006980), quercetin (MOL000098) and kaempferol (MOL000422), have high molecular interaction ability with the ED-related targets, indicating that quercetin, papaverine and kaempferol are the main active components of ginseng for improving ED, and their mechanism of action is related to their binding and regulation of these targets. Among them, papaverine can interact with PDE5A, PDE2A and PDE10A in the PDE family. The PDE family is a typical ED intervention target, for example, drugs such as sildenafil take PDE5 as the efficacy target. Quercetin and kaempferol can both significantly interact with ESR2, EGFR, IGF1R, KDR, MET, GSK3B, CDK2, PIM1 and CDK1, and such targets play an important role in the pathogenesis of ED. Therefore, the results of molecular docking show that ginseng can improve ED by affecting the targets described in Table 1. For example, papaverine in ginseng can increase the level of cGMP by inhibiting the activity of PDE5A, thereby promoting smooth muscle relaxation and blood flow increase; daucosterin_qt (MOL005399) in ginseng can increase androgen signaling by activating AR, thereby improving sexual desire and sexual function; quercetin and kaempferol in ginseng can expand blood vessels and improve endothelial function by regulating the activity of ESR2, EGFR, IGF1R, etc.

[0064] Finally, it should be noted that the above only describes the preferred embodiments of the present application and is not intended to limit the present application. Although the present application has been described in detail with reference to the foregoing embodiments, those skilled in the art can still modify the technical solutions described in the foregoing embodiments or make equivalent replacements to some technical features. Any modifications, equivalent replacements, improvements, etc. made within the spirit and principles of the present application shall be included in the protection scope of the present application.

Claims

1. A method for analyzing the mechanism of action of ginseng in improving erectile dysfunction, characterized in that, Includes the following steps: S1. The active ingredients of ginseng were obtained by searching the SymMap database of traditional Chinese medicine syndrome associations, the database of traditional Chinese medicine systems pharmacology, and the TCMSP analysis platform. The active ingredients include the components contained in ginseng itself and the active substances produced by human metabolism. The TCMSP search keyword was "ginseng", and the screening conditions were: oral bioavailability OB≥30%; drug similarity DL≥0.18; Caco-2 permeability≥-0.

4. The SymMap search keyword was "ginseng", and the screening conditions were: 0.3 kDa≤molecular weight≤1.5 kDa. The number of hydrogen bond donors is less than or equal to 5; the number of hydrogen bond acceptors is ≤10; the polar surface area is ≤140 Ų; -1 ≤ logarithmic distribution coefficient LogP ≤5; S2. Use the SwissTargetPrediction tool to screen targets with a probability greater than 0 of interacting with the active ingredient as potential targets. S3. Identify potential targets related to erectile dysfunction; S4. Based on the above results, construct a "functional component-target-disease" network diagram of ginseng, obtain the common targets related to the functional components and erectile dysfunction, and perform enrichment analysis on the key targets with a mediating centrality > 0.1 among the common targets. S5. Perform molecular interaction analysis and verification on the common target and the corresponding ginseng efficacy components.

2. The method for analyzing the mechanism of action of ginseng in improving erectile dysfunction according to claim 1, characterized in that: Step S3 involves obtaining potential targets related to erectile dysfunction from the OMIM and GeneCards databases.

3. The method for analyzing the mechanism of action of ginseng in improving erectile dysfunction according to claim 1, characterized in that: The enrichment analysis described in step S4 includes GO functional enrichment analysis and KEGG pathway enrichment analysis.

4. The method for analyzing the mechanism of action of ginseng in improving erectile dysfunction according to claim 1, characterized in that: In step S5, the tertiary structure of the common target in step S4 is obtained through the protein structure database PDB, and the molecular interaction ability of the common target and the corresponding ginseng efficacy components is analyzed and verified using the molecular docking tool CB-Dock.

5. The method for analyzing the mechanism of action of ginseng in improving erectile dysfunction according to claim 4, characterized in that: The receptor protein for molecular docking is obtained by screening for mediating centrality as described in step S4, and the ligand molecule is the ginseng active ingredient obtained in step S1.

6. The method for analyzing the mechanism of action of ginseng in improving erectile dysfunction according to claim 5, characterized in that: Targets with a median centrality >0.1 and a probability of interaction with ginseng active ingredients >30% were selected as receptor proteins.

Images